{"pmid":32283980,"title":"Clinical Presentation of COVID-19: A Systematic Review Focusing on Upper Airway Symptoms.","text":["Clinical Presentation of COVID-19: A Systematic Review Focusing on Upper Airway Symptoms.","AIM: Pharyngodynia, nasal congestion, rhinorrhea, smell, and taste dysfunctions could be the presenting symptoms of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2. The aim was to perform a systematic review of current evidences on clinical presentation of COVID-19, focusing on upper airway symptoms in order to help otolaryngologists identifying suspected cases. METHODS: We searched PubMed and Web of Science electronic databases. RESULTS: We included 5 retrospective clinical studies for a total of 1556 hospitalized patients with COVID-19, 57.5% were male and mean age was 49.1 years. Pooled data revealed that pharyngodynia was present in 12.4% of patients, nasal congestion in 3.7%, and rhinorrhea was rare. No reports on COVID-19 and olfactory/gustative disorders matched inclusion criteria but preliminary evidences suggested they could be present. Common symptoms were fever (85.6%), cough (68.7%), and fatigue (39.4%). Frequent comorbidities were hypertension (17.4%), diabetes (3.8%), and coronary heart disease (3.8%); 83% of patients had alterations on chest computed tomography that were bilateral in 89.5% of cases. Ground-glass opacity was the most common finding (50%). Lymphopenia (77.2%) and leucopenia (30.1%) were common. Critical cases with complications were 9%, intensive care unit admission was required in 7.3%, invasive ventilation in 3.4%, and mortality was 2.4%. CONCLUSION: Otolaryngologists should know that pharyngodynia, nasal congestion, olfactory, and gustative disorders could be the presenting symptoms of COVID-19. Clinical presentation together with radiological and laboratory findings could help to identify suspected cases.","Ear Nose Throat J","Lovato, Andrea","de Filippis, Cosimo","32283980"],"abstract":["AIM: Pharyngodynia, nasal congestion, rhinorrhea, smell, and taste dysfunctions could be the presenting symptoms of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2. The aim was to perform a systematic review of current evidences on clinical presentation of COVID-19, focusing on upper airway symptoms in order to help otolaryngologists identifying suspected cases. METHODS: We searched PubMed and Web of Science electronic databases. RESULTS: We included 5 retrospective clinical studies for a total of 1556 hospitalized patients with COVID-19, 57.5% were male and mean age was 49.1 years. Pooled data revealed that pharyngodynia was present in 12.4% of patients, nasal congestion in 3.7%, and rhinorrhea was rare. No reports on COVID-19 and olfactory/gustative disorders matched inclusion criteria but preliminary evidences suggested they could be present. Common symptoms were fever (85.6%), cough (68.7%), and fatigue (39.4%). Frequent comorbidities were hypertension (17.4%), diabetes (3.8%), and coronary heart disease (3.8%); 83% of patients had alterations on chest computed tomography that were bilateral in 89.5% of cases. Ground-glass opacity was the most common finding (50%). Lymphopenia (77.2%) and leucopenia (30.1%) were common. Critical cases with complications were 9%, intensive care unit admission was required in 7.3%, invasive ventilation in 3.4%, and mortality was 2.4%. CONCLUSION: Otolaryngologists should know that pharyngodynia, nasal congestion, olfactory, and gustative disorders could be the presenting symptoms of COVID-19. Clinical presentation together with radiological and laboratory findings could help to identify suspected cases."],"journal":"Ear Nose Throat J","authors":["Lovato, Andrea","de Filippis, Cosimo"],"date":"2020-04-15T11:00:00Z","year":2020,"_id":"32283980","week":"202016|Apr 13 - Apr 19","doi":"10.1177/0145561320920762","keywords":["COVID-19","SARS-CoV-2","nasal congestion","pharyngodynia","smell","taste"],"source":"PubMed","topics":["Diagnosis"],"weight":1,"locations":["Pharyngodynia","pharyngodynia","pharyngodynia"],"_version_":1664071627187421184,"score":8.233237,"similar":[{"pmid":32253535,"title":"Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study.","text":["Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study.","OBJECTIVE: To investigate the occurrence of olfactory and gustatory dysfunctions in patients with laboratory-confirmed COVID-19 infection. METHODS: Patients with laboratory-confirmed COVID-19 infection were recruited from 12 European hospitals. The following epidemiological and clinical outcomes have been studied: age, sex, ethnicity, comorbidities, and general and otolaryngological symptoms. Patients completed olfactory and gustatory questionnaires based on the smell and taste component of the National Health and Nutrition Examination Survey, and the short version of the Questionnaire of Olfactory Disorders-Negative Statements (sQOD-NS). RESULTS: A total of 417 mild-to-moderate COVID-19 patients completed the study (263 females). The most prevalent general symptoms consisted of cough, myalgia, and loss of appetite. Face pain and nasal obstruction were the most disease-related otolaryngological symptoms. 85.6% and 88.0% of patients reported olfactory and gustatory dysfunctions, respectively. There was a significant association between both disorders (p < 0.001). Olfactory dysfunction (OD) appeared before the other symptoms in 11.8% of cases. The sQO-NS scores were significantly lower in patients with anosmia compared with normosmic or hyposmic individuals (p = 0.001). Among the 18.2% of patients without nasal obstruction or rhinorrhea, 79.7% were hyposmic or anosmic. The early olfactory recovery rate was 44.0%. Females were significantly more affected by olfactory and gustatory dysfunctions than males (p = 0.001). CONCLUSION: Olfactory and gustatory disorders are prevalent symptoms in European COVID-19 patients, who may not have nasal symptoms. The sudden anosmia or ageusia need to be recognized by the international scientific community as important symptoms of the COVID-19 infection.","Eur Arch Otorhinolaryngol","Lechien, Jerome R","Chiesa-Estomba, Carlos M","De Siati, Daniele R","Horoi, Mihaela","Le Bon, Serge D","Rodriguez, Alexandra","Dequanter, Didier","Blecic, Serge","El Afia, Fahd","Distinguin, Lea","Chekkoury-Idrissi, Younes","Hans, Stephane","Delgado, Irene Lopez","Calvo-Henriquez, Christian","Lavigne, Philippe","Falanga, Chiara","Barillari, Maria Rosaria","Cammaroto, Giovanni","Khalife, Mohamad","Leich, Pierre","Souchay, Christel","Rossi, Camelia","Journe, Fabrice","Hsieh, Julien","Edjlali, Myriam","Carlier, Robert","Ris, Laurence","Lovato, Andrea","De Filippis, Cosimo","Coppee, Frederique","Fakhry, Nicolas","Ayad, Tareck","Saussez, Sven","32253535"],"abstract":["OBJECTIVE: To investigate the occurrence of olfactory and gustatory dysfunctions in patients with laboratory-confirmed COVID-19 infection. METHODS: Patients with laboratory-confirmed COVID-19 infection were recruited from 12 European hospitals. The following epidemiological and clinical outcomes have been studied: age, sex, ethnicity, comorbidities, and general and otolaryngological symptoms. Patients completed olfactory and gustatory questionnaires based on the smell and taste component of the National Health and Nutrition Examination Survey, and the short version of the Questionnaire of Olfactory Disorders-Negative Statements (sQOD-NS). RESULTS: A total of 417 mild-to-moderate COVID-19 patients completed the study (263 females). The most prevalent general symptoms consisted of cough, myalgia, and loss of appetite. Face pain and nasal obstruction were the most disease-related otolaryngological symptoms. 85.6% and 88.0% of patients reported olfactory and gustatory dysfunctions, respectively. There was a significant association between both disorders (p < 0.001). Olfactory dysfunction (OD) appeared before the other symptoms in 11.8% of cases. The sQO-NS scores were significantly lower in patients with anosmia compared with normosmic or hyposmic individuals (p = 0.001). Among the 18.2% of patients without nasal obstruction or rhinorrhea, 79.7% were hyposmic or anosmic. The early olfactory recovery rate was 44.0%. Females were significantly more affected by olfactory and gustatory dysfunctions than males (p = 0.001). CONCLUSION: Olfactory and gustatory disorders are prevalent symptoms in European COVID-19 patients, who may not have nasal symptoms. The sudden anosmia or ageusia need to be recognized by the international scientific community as important symptoms of the COVID-19 infection."],"journal":"Eur Arch Otorhinolaryngol","authors":["Lechien, Jerome R","Chiesa-Estomba, Carlos M","De Siati, Daniele R","Horoi, Mihaela","Le Bon, Serge D","Rodriguez, Alexandra","Dequanter, Didier","Blecic, Serge","El Afia, Fahd","Distinguin, Lea","Chekkoury-Idrissi, Younes","Hans, Stephane","Delgado, Irene Lopez","Calvo-Henriquez, Christian","Lavigne, Philippe","Falanga, Chiara","Barillari, Maria Rosaria","Cammaroto, Giovanni","Khalife, Mohamad","Leich, Pierre","Souchay, Christel","Rossi, Camelia","Journe, Fabrice","Hsieh, Julien","Edjlali, Myriam","Carlier, Robert","Ris, Laurence","Lovato, Andrea","De Filippis, Cosimo","Coppee, Frederique","Fakhry, Nicolas","Ayad, Tareck","Saussez, Sven"],"date":"2020-04-08T11:00:00Z","year":2020,"_id":"32253535","week":"202015|Apr 06 - Apr 12","doi":"10.1007/s00405-020-05965-1","keywords":["Anosmia","COVID","COVID-19","Coronavirus","Dysgeusia","ENT","Gustatory","Hyposmia","Infection","Loss","Olfaction","Olfactory","SARS-CoV-2","Smell","Taste"],"source":"PubMed","locations":["European","myalgia"],"topics":["Diagnosis"],"weight":1,"_version_":1663450393554714624,"score":454.4229},{"pmid":32283155,"pmcid":"PMC7151416","title":"Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: a systematic review and meta-analysis.","text":["Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: a systematic review and meta-analysis.","OBJECTIVE: To better inform efforts to treat and control the current outbreak with a comprehensive characterization of COVID-19. METHODS: We searched PubMed, EMBASE, Web of Science, and CNKI (Chinese Database) for studies published as of March 2, 2020, and we searched references of identified articles. Studies were reviewed for methodological quality. A random-effects model was used to pool results. Heterogeneity was assessed using I(2). Publication bias was assessed using Egger's test. RESULTS: 43 studies involving 3600 patients were included. Among COVID-19 patients, fever (83.3% [95% CI 78.4-87.7]), cough (60.3% [54.2-66.3]), and fatigue (38.0% [29.8-46.5]) were the most common clinical symptoms. The most common laboratory abnormalities were elevated C-reactive protein (68.6% [58.2-78.2]), decreased lymphocyte count (57.4% [44.8-69.5]) and increased lactate dehydrogenase (51.6% [31.4-71.6]). Ground-glass opacities (80.0% [67.3-90.4]) and bilateral pneumonia (73.2% [63.4-82.1]) were the most frequently reported findings on computed tomography. The overall estimated proportion of severe cases and case-fatality rate (CFR) was 25.6% (17.4-34.9) and 3.6% (1.1-7.2), respectively. CFR and laboratory abnormalities were higher in severe cases, patients from Wuhan, and older patients, but CFR did not differ by gender. CONCLUSIONS: The majority of COVID-19 cases are symptomatic with a moderate CFR. Patients living in Wuhan, older patients, and those with medical comorbidities tend to have more severe clinical symptoms and higher CFR.","J Infect","Fu, Leiwen","Wang, Bingyi","Yuan, Tanwei","Chen, Xiaoting","Ao, Yunlong","Fitzpatrick, Tom","Li, Peiyang","Zhou, Yiguo","Lin, Yifan","Duan, Qibin","Luo, Ganfeng","Fan, Song","Lu, Yong","Feng, Anping","Zhan, Yuewei","Liang, Bowen","Cai, Weiping","Zhang, Lin","Du, Xiangjun","Shu, Yuelong","Li, Linghua","Zou, Huachun","32283155"],"abstract":["OBJECTIVE: To better inform efforts to treat and control the current outbreak with a comprehensive characterization of COVID-19. METHODS: We searched PubMed, EMBASE, Web of Science, and CNKI (Chinese Database) for studies published as of March 2, 2020, and we searched references of identified articles. Studies were reviewed for methodological quality. A random-effects model was used to pool results. Heterogeneity was assessed using I(2). Publication bias was assessed using Egger's test. RESULTS: 43 studies involving 3600 patients were included. Among COVID-19 patients, fever (83.3% [95% CI 78.4-87.7]), cough (60.3% [54.2-66.3]), and fatigue (38.0% [29.8-46.5]) were the most common clinical symptoms. The most common laboratory abnormalities were elevated C-reactive protein (68.6% [58.2-78.2]), decreased lymphocyte count (57.4% [44.8-69.5]) and increased lactate dehydrogenase (51.6% [31.4-71.6]). Ground-glass opacities (80.0% [67.3-90.4]) and bilateral pneumonia (73.2% [63.4-82.1]) were the most frequently reported findings on computed tomography. The overall estimated proportion of severe cases and case-fatality rate (CFR) was 25.6% (17.4-34.9) and 3.6% (1.1-7.2), respectively. CFR and laboratory abnormalities were higher in severe cases, patients from Wuhan, and older patients, but CFR did not differ by gender. CONCLUSIONS: The majority of COVID-19 cases are symptomatic with a moderate CFR. Patients living in Wuhan, older patients, and those with medical comorbidities tend to have more severe clinical symptoms and higher CFR."],"journal":"J Infect","authors":["Fu, Leiwen","Wang, Bingyi","Yuan, Tanwei","Chen, Xiaoting","Ao, Yunlong","Fitzpatrick, Tom","Li, Peiyang","Zhou, Yiguo","Lin, Yifan","Duan, Qibin","Luo, Ganfeng","Fan, Song","Lu, Yong","Feng, Anping","Zhan, Yuewei","Liang, Bowen","Cai, Weiping","Zhang, Lin","Du, Xiangjun","Shu, Yuelong","Li, Linghua","Zou, Huachun"],"date":"2020-04-14T11:00:00Z","year":2020,"_id":"32283155","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.jinf.2020.03.041","keywords":["COVID-19","clinical characteristics","meta-analysis","systematic review"],"source":"PubMed","topics":["Diagnosis"],"weight":1,"locations":["Chinese","Wuhan","Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664182200787009536,"score":289.75906},{"pmid":32271490,"title":"A primer on viral-associated olfactory loss in the era of COVID-19.","text":["A primer on viral-associated olfactory loss in the era of COVID-19.","Early reports have suggested that smell loss may be an early symptom associated with the pandemic known as COVID-19. The possibility that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) might cause olfactory dysfunction is certainly plausible. Patients presenting to specialized smell clinics are commonly diagnosed with upper respiratory infection (URI)-associated olfactory loss and most are presumed to be viral related. In acute phases of infection, it is common to experience some smell loss as a result of nasal inflammation, mucosal edema, and obstruction of airflow into the olfactory cleft. In most cases, these episodes of smell loss are self-limiting and coincide with resolution of URI symptoms. However, in some cases the smell loss persists for months to years and this is presumed to occur through a more direct olfactory insult by the virus. It remains too early to know whether infection with SARS-CoV-2 causes persistent olfactory dysfunction. However, given the scale of this pandemic, if SARS-CoV-2 does cause chronic olfactory loss in even a small portion of those infected, then the overall population prevalence could be quite large. This review provides a brief, practical overview of viral-associated olfactory loss, realizing that evidence related to COVID-19 will likely not be clear for some time. Our goal is to highlight the existence and importance of this condition and provide information geared for both providers and patients. Practical suggestions regarding evaluation and treatment will be provided, realizing that there may be constraints on medical resources and the nature of this pandemic remains dynamic. This article is protected by copyright. All rights reserved.","Int Forum Allergy Rhinol","Soler, Zachary M","Patel, Zara M","Turner, Justin H","Holbrook, Eric H","32271490"],"abstract":["Early reports have suggested that smell loss may be an early symptom associated with the pandemic known as COVID-19. The possibility that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) might cause olfactory dysfunction is certainly plausible. Patients presenting to specialized smell clinics are commonly diagnosed with upper respiratory infection (URI)-associated olfactory loss and most are presumed to be viral related. In acute phases of infection, it is common to experience some smell loss as a result of nasal inflammation, mucosal edema, and obstruction of airflow into the olfactory cleft. In most cases, these episodes of smell loss are self-limiting and coincide with resolution of URI symptoms. However, in some cases the smell loss persists for months to years and this is presumed to occur through a more direct olfactory insult by the virus. It remains too early to know whether infection with SARS-CoV-2 causes persistent olfactory dysfunction. However, given the scale of this pandemic, if SARS-CoV-2 does cause chronic olfactory loss in even a small portion of those infected, then the overall population prevalence could be quite large. This review provides a brief, practical overview of viral-associated olfactory loss, realizing that evidence related to COVID-19 will likely not be clear for some time. Our goal is to highlight the existence and importance of this condition and provide information geared for both providers and patients. Practical suggestions regarding evaluation and treatment will be provided, realizing that there may be constraints on medical resources and the nature of this pandemic remains dynamic. This article is protected by copyright. All rights reserved."],"journal":"Int Forum Allergy Rhinol","authors":["Soler, Zachary M","Patel, Zara M","Turner, Justin H","Holbrook, Eric H"],"date":"2020-04-10T11:00:00Z","year":2020,"_id":"32271490","week":"202015|Apr 06 - Apr 12","doi":"10.1002/alr.22578","keywords":["coronavirus, smell","olfaction","post-viral","upper respiratory infection"],"source":"PubMed","topics":["Mechanism","Treatment","Diagnosis"],"weight":1,"_version_":1663620083129253889,"score":288.58606},{"pmid":32232218,"pmcid":"PMC7096724","title":"Prevalence of Underlying Diseases in Hospitalized Patients with COVID-19: a Systematic Review and Meta-Analysis.","text":["Prevalence of Underlying Diseases in Hospitalized Patients with COVID-19: a Systematic Review and Meta-Analysis.","Introduction: In the beginning of 2020, an unexpected outbreak due to a new corona virus made the headlines all over the world. Exponential growth in the number of those affected makes this virus such a threat. The current meta-analysis aimed to estimate the prevalence of underlying disorders in hospitalized COVID-19 patients. Methods: A comprehensive systematic search was performed on PubMed, Scopus, Web of science, and Google scholar, to find articles published until 15 February 2020. All relevant articles that reported clinical characteristics and epidemiological information of hospitalized COVID-19 patients were included in the analysis. Results: The data of 76993 patients presented in 10 articles were included in this study. According to the meta-analysis, the pooled prevalence of hypertension, cardiovascular disease, smoking history and diabetes in people infected with SARS-CoV-2 were estimated as 16.37% (95%CI: 10.15%-23.65%), 12.11% (95%CI 4.40%-22.75%), 7.63% (95%CI 3.83%-12.43%) and 7.87% (95%CI 6.57%-9.28%), respectively. Conclusion: According to the findings of the present study, hypertension, cardiovascular diseases, diabetes mellitus, smoking, chronic obstructive pulmonary disease (COPD), malignancy, and chronic kidney disease were among the most prevalent underlying diseases among hospitalized COVID-19 patients, respectively.","Arch Acad Emerg Med","Emami, Amir","Javanmardi, Fatemeh","Pirbonyeh, Neda","Akbari, Ali","32232218"],"abstract":["Introduction: In the beginning of 2020, an unexpected outbreak due to a new corona virus made the headlines all over the world. Exponential growth in the number of those affected makes this virus such a threat. The current meta-analysis aimed to estimate the prevalence of underlying disorders in hospitalized COVID-19 patients. Methods: A comprehensive systematic search was performed on PubMed, Scopus, Web of science, and Google scholar, to find articles published until 15 February 2020. All relevant articles that reported clinical characteristics and epidemiological information of hospitalized COVID-19 patients were included in the analysis. Results: The data of 76993 patients presented in 10 articles were included in this study. According to the meta-analysis, the pooled prevalence of hypertension, cardiovascular disease, smoking history and diabetes in people infected with SARS-CoV-2 were estimated as 16.37% (95%CI: 10.15%-23.65%), 12.11% (95%CI 4.40%-22.75%), 7.63% (95%CI 3.83%-12.43%) and 7.87% (95%CI 6.57%-9.28%), respectively. Conclusion: According to the findings of the present study, hypertension, cardiovascular diseases, diabetes mellitus, smoking, chronic obstructive pulmonary disease (COPD), malignancy, and chronic kidney disease were among the most prevalent underlying diseases among hospitalized COVID-19 patients, respectively."],"journal":"Arch Acad Emerg Med","authors":["Emami, Amir","Javanmardi, Fatemeh","Pirbonyeh, Neda","Akbari, Ali"],"date":"2020-04-02T11:00:00Z","year":2020,"_id":"32232218","week":"202014|Mar 30 - Apr 05","keywords":["COVID-19","Comorbidity","Meta-analysis","severe acute respiratory syndrome coronavirus 2"],"source":"PubMed","topics":["Diagnosis"],"weight":1,"_version_":1663352135424671744,"score":276.60187},{"pmid":32301284,"title":"Smell dysfunction: a biomarker for COVID-19.","text":["Smell dysfunction: a biomarker for COVID-19.","BACKGROUND: SARS-CoV-2, the virus that causes COVID-19 disease, is responsible for the largest pandemic since the 1918 H1N1 influenza outbreak. The symptoms presently recognized by the World Health Organization are cough, fever, tiredness, and difficulty breathing. Patient-reported smell and taste loss has been associated with COVID-19 infection, yet no empirical olfactory testing on a cohort of COVID-19 patients has been performed. METHODS: The University of Pennsylvania Smell Identification Test (UPSIT), a well-validated 40-odorant test, was administered to 60 confirmed COVID-19 inpatients and 60 age- and sex-matched controls to assess the magnitude and frequency of their olfactory dysfunction. A mixed effects analysis of variance determined whether meaningful differences in test scores existed between the two groups and if the test scores were differentially influenced by sex. RESULTS: Fifty-nine (98%) of the 60 patients exhibited some smell dysfunction [mean (95% CI) UPSIT score: 20.98 (19.47,22.48); controls: 34.10 (33.31,34.88); p<0.0001]. Thirty-five of the 60 patients (58%) were either anosmic (15/60; 25%) or severely microsmic (20/60; 33%); 16 exhibited moderate microsmia (16/60; 27%), 8 mild microsmia (8/60; 13%), and one normosmia (1/60; 2%). Deficits were evident for all 40 UPSIT odorants. No meaningful relationships between the test scores and sex, disease severity, or comorbidities were found. CONCLUSIONS: Quantitative smell testing demonstrates that decreased smell function, but not always anosmia, is a major marker for SARS-CoV-2 infection and suggests the possibility that smell testing may help, in some cases, to identify COVID-19 patients in need of early treatment or quarantine. This article is protected by copyright. All rights reserved.","Int Forum Allergy Rhinol","Moein, Shima T","Hashemian, Seyed M R","Mansourafshar, Babak","Khorram-Tousi, Ali","Tabarsi, Payam","Doty, Richard L","32301284"],"abstract":["BACKGROUND: SARS-CoV-2, the virus that causes COVID-19 disease, is responsible for the largest pandemic since the 1918 H1N1 influenza outbreak. The symptoms presently recognized by the World Health Organization are cough, fever, tiredness, and difficulty breathing. Patient-reported smell and taste loss has been associated with COVID-19 infection, yet no empirical olfactory testing on a cohort of COVID-19 patients has been performed. METHODS: The University of Pennsylvania Smell Identification Test (UPSIT), a well-validated 40-odorant test, was administered to 60 confirmed COVID-19 inpatients and 60 age- and sex-matched controls to assess the magnitude and frequency of their olfactory dysfunction. A mixed effects analysis of variance determined whether meaningful differences in test scores existed between the two groups and if the test scores were differentially influenced by sex. RESULTS: Fifty-nine (98%) of the 60 patients exhibited some smell dysfunction [mean (95% CI) UPSIT score: 20.98 (19.47,22.48); controls: 34.10 (33.31,34.88); p<0.0001]. Thirty-five of the 60 patients (58%) were either anosmic (15/60; 25%) or severely microsmic (20/60; 33%); 16 exhibited moderate microsmia (16/60; 27%), 8 mild microsmia (8/60; 13%), and one normosmia (1/60; 2%). Deficits were evident for all 40 UPSIT odorants. No meaningful relationships between the test scores and sex, disease severity, or comorbidities were found. CONCLUSIONS: Quantitative smell testing demonstrates that decreased smell function, but not always anosmia, is a major marker for SARS-CoV-2 infection and suggests the possibility that smell testing may help, in some cases, to identify COVID-19 patients in need of early treatment or quarantine. This article is protected by copyright. All rights reserved."],"journal":"Int Forum Allergy Rhinol","authors":["Moein, Shima T","Hashemian, Seyed M R","Mansourafshar, Babak","Khorram-Tousi, Ali","Tabarsi, Payam","Doty, Richard L"],"date":"2020-04-18T11:00:00Z","year":2020,"_id":"32301284","week":"202016|Apr 13 - Apr 19","doi":"10.1002/alr.22587","keywords":["biomarker","chronic rhinosinusitis","olfaction","olfactory disorders","olfactory test","rhinitis","upsit"],"source":"PubMed","topics":["Diagnosis"],"weight":1,"_version_":1664357978621345793,"score":267.05707}]}